Immunovia Ab · OMXSTO:IMMNOV
Immunovia Ab — Q1 2025 Earnings Presentation
20 slides from Immunovia Ab's earnings presentation, May 14, 2025
Slide 1: Dial-in numbers
• Sweden: +46 (0)8 5051 0031 United Kingdom: +44 (0) 207 107 06 13 United States: +1 (1) 631 570 56 13 • •
Slide 2: Immunovia
mm: « ° » Simmunovia
Slide 3: Saving lives through early detection of pancreatic cancer
Saving lives through early detection of pancreatic cancer
Slide 4: Patient quote: looking for a product that provides peace of mind
“I’m in my forties with a young family, so I’m looking for a product that will provide us peace of mind”
Slide 5: Launch preparations for the PancreaSure test are on track for September 2025
Our launch preparations 1 Clinical study results to support reimbursement: VERIFI for the PancreaSure test are on track for a 2 Commercial launch preparations September 2025 debut, fueled by successful clinical studies and strong 3 Strategic partner discussions interest from both physicians and 4 Q1
Slide 6: The VERIFI clinical validation study included 386 rare blood samples
INSTITUTIONS THAT SUPPORTED THE STUDY WITH BLOOD SAMPLES The VERIFI clinical validation study included 386 rare blood samples from top pancreatic cancer centers 115 271 Stage 1 & 2 pancreatic High-risk cancer cases controls
Slide 7: PancreaSure demonstrated 77% sensitivity and 88% specificity in VERIFI
Sensitivity The PancreaSure 77% With sensitivity of 77%, we would test demonstrated detect cancer in more than 3 out of 77% sensitivity and every 4 patients with stage 1 or 2 PDAC 88% specificity in the VERIFI study of 386 challenging blood samples Specificity 88% With specificity of 88%, we would h
Slide 8: PancreaSure test performance compares very favorably to imaging
ACCURACY IN DETECTING STAGE 1 AND 2 PANCREATIC CANCER IN A META-ANALYSIS (2,3) 100% Hundreds PancreaSure test performance 75% compares very favorably to imaging, is much more 50% convenient and less costly 25% 0% Endoscopic Ultrasound MRI CT Sensitivity Specificity 1. Data on file. 2. Sakamoto H, Ki
Slide 9: The next-generation test performs very well across patient risk groups
The next-generation test performs very well across different patient risk groups in combined data from VERIFI & CLARITI
Slide 10: Combined VERIFI & CLARITI performance across risk groups
The next-generation test performs very well across different patient risk groups in combined data from VERIFI & CLARITI Risk Group Cases Controls Sensitivity Specificity Overall 317 1,134 78% 92% Familial/Genetic 71 922 78% 94% Diabetes 128 105 80% 90% Cysts 79 426 72% 89% The combined test performa
Slide 11: Our transition to the commercial phase is progressing very well
Our transition to the commercial phase is progressing very well DEVELOPMENT PHASE COMMERCIAL PHASE Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Analytical Clinical Conduct Additional Studies to Support Model Development Validation Validation Reimbursement Completed Upcoming Secure Commercia
Slide 12: Physician and patient interest in the PancreaSure test is surging
High-value physician targets defined Physician and patient interest in Designing efficient processes, automation, and outsourcing to lower our costs the PancreaSure test is surging as Advocacy groups are mobilizing we prepare for a Launched a more modern and energetic brand as successful launch well
Slide 13: We are designing efficient, automated processes to drive sales and reduce costs
We are designing efficient, automated processes to drive sales and reduce costs
Slide 14: oer.
oer. os immunovia
Slide 15: The PancreaSure test: Accurate, simple, convenient
The PancreaSure test — Accurate, simple, convenient PancreaSure is a simple blood test proven to detect pancreatic cancer at stage 1 and 2 with high accuracy. I's for people at elevated risk for pancreatic cancer due to family history or genetic mutations. PancreaSure detects proteins and other biom
Slide 16: Key opinion leaders responded enthusiastically to PancreaSure data
Key opinion leaders and top clinicians responded enthusiastically to PancreaSure data at Digestive Disease Week and the American Association of Cancer Research meeting
Slide 17: Cash balance, burn and runway
Cash balance, burn and runway • Cash balance 37.7 MSEK as of end Q1 • Cash burn was 8.1 MSEK per month, at the low end of guidance • Cash burn expected to be 8-10 MSEK per month; focus on commercialization and clinical studies to support reimbursement • Current cash should fund capital needs through
Slide 18: Immunovia offers a compelling investment opportunity
Immunovia offers a compelling investment opportunity Attractive Valuation Valuable Assets Upcoming Catalysts MARKET CAPITALIZATION Fully developed pancreatic Commercial launch in the US in 118 MSEK cancer detection test Two successful clinical September 2025 Additional clinical study results validat
Slide 19: » Simmunovia
mm: « ° » Simmunovia
Slide 20: Questions
#simmunovia a » . > Questions